AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19845100
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate 40 mg injection
Trial: 16757756
Drug: Augmentation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation with porcine small intestine mucosa
Trial: 20467596
Drug: No augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No augmentation (Control)
Trial: 15004874
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg qd) for 12 weeks
Trial: 9262274
Drug: Physician-administered fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Physician-administered fentanyl
Trial: 22994896
Drug: Inhaled anesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled anesthetics
Trial: 25319879
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy with defibrillator (CRT-D)
Trial: 23336504
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) intervention with Standard Health Care Advice (SHCA)
Trial: 18042987
Drug: 500‐microg F/g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500‐microg F/g (NaF) dentifrice
Trial: 18042987
Drug: 1,100‐microg F/g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,100‐microg F/g dentifrice
Trial: 16209659
Drug: Moxonidine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (0.6 mg)
Trial: 1390375
Drug: 0.5mg intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg intrathecal morphine with 3 mls of 0.5% intrathecal bupivacine
Trial: 30079637
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) + 5000 ppm sodium fluoride (GLASER)
Trial: 27212226
Drug: Transdiagnostic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic group cognitive behavioral therapy (TGCBT) for anxiety over 12 weeks
Trial: 25016974
Drug: Psychodynamic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic Therapy
Trial: 22873492
Drug: Amoxicillin plus
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin plus clavulanic acid vs Sodium benzoate
Trial: 21049208
Drug: Group PK
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group PK (0.15 mg/kg ketamine + 80 ml 0.5% prilocaine)
Trial: 21049208
Drug: Group P
RxNorm normalized name: High mobility group protein HMGI-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P (80 ml 0.5% prilocaine)
Trial: 15816475
Drug: Interferon alpha-2b/ribavirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b/ribavirin combination therapy
Trial: 15816475
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b monotherapy
Trial: 11443628
Drug: Infusional cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusional cyclophosphamide (187.5 mg/m² per day), doxorubicin (12.5 mg/m² per day), and etoposide (60 mg/m² per day) administered as second-line chemotherapy for 96 hours continuous intravenous infusion.
Trial: 8079928
Drug: Cimetidine plus
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine plus amoxycillin (500 mg three times a day for 2 weeks) and metronidazole (250 mg three times a day for 2 weeks)
Trial: 8079928
Drug: Cimetidine alone
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine alone (800 mg at night for 4 weeks)
Trial: 786681
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine sulphate (0.25, 0.40, 0.75 and 1.50 mg)
Trial: 786681
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine methylnitrate (0.08, 0.13 and 0.25 mg)
Trial: 30755234
Drug: Carbohydrate supplements
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplements (CHO)
Trial: 17590218
Drug: Nimesulide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (100 mg twice a day)
Trial: 17590218
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg once a day)
Trial: 14733608
Drug: IVIg plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg plus IFNalpha (400 mg/kg each day for 5 days, then 3 MUI of leucocyte IFNalpha three times a week)
Trial: 14733608
Drug: IFNalpha alone
RxNorm normalized name: Zenalpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNalpha alone (physiological solution followed by leucocyte IFNalpha three times a week for 6 months)
Trial: 11669086
Drug: Olanzapine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (20-40 mg/d)
Trial: 1180024
Drug: Non-operated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operated group (conservative treatment)
Trial: 31075442
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (2 L in divided doses)
Trial: 23575965
Drug: Pasireotide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide (600 μg or 900 μg) subcutaneously twice daily for 3 months
Trial: 23575965
Drug: CushingQOL questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CushingQOL questionnaire self-administered at baseline, month 3, month 6, and month 12
Trial: 15372361
Drug: Metformin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (750 mg/day) for 6 months
Trial: 9347208
Drug: Misoprostol 800
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 800 micrograms self-administered vaginally 3 days after methotrexate
Trial: 9347208
Drug: Misoprostol 800
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 800 micrograms self-administered vaginally 4 days after methotrexate
Trial: 9347208
Drug: Misoprostol 800
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 800 micrograms self-administered vaginally 5 days after methotrexate
Trial: 2285656
Drug: Ketanserin, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin, 40 mg twice daily for 1 week
Trial: 22660805
Drug: Pegloticase 8
RxNorm normalized name: pegloticase 8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegloticase 8 mg biweekly (twice monthly)
Trial: 22660805
Drug: Pegloticase 8
RxNorm normalized name: pegloticase 8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegloticase 8 mg monthly (alternating with placebo)
Trial: 18832341
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (0.16 mJ/mm(2); 2000 impulses)
Trial: 16027282
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy with or without concurrent chemotherapy
Trial: 8624220
Drug: Citicoline 1000
RxNorm normalized name: citicoline 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline 1000 mg/d for 3 months
Trial: 8624220
Drug: Citicoline 2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline 2000 mg/d for 2 months
Trial: 22853197
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches (eight-week, step down program) dispensed at discharge
Trial: 22853197
Drug: Combined interventions
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined interventions (nicotine patches and telephone counseling)
Trial: 22853197
Drug: All interventions
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All interventions (patch alone, counseling alone, and combined interventions)
Trial: 18832497
Drug: Second-generation antidepressants
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antidepressants
Trial: 17377748
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) 0.2 mg/ml applied to the osteotomy site for 30 min
Trial: 12077687
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d enalapril
Trial: 9445316
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 250,000 IU intrapleural streptokinase (IPSK)
Trial: 9445316
Drug: Serial doses
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial doses of 250,000 IU intrapleural streptokinase (IPSK) every 12 hours for 3 days (total dose: 1.5 million IU)
Trial: 8711268
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg per os 1 h before exercise
Trial: 2315637
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine butylbromide (Buscopan) 20 mg i.v.
Trial: 2315637
Drug: Glucagon 1
RxNorm normalized name: GLUCAGON 1MG/VI INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon 1 mg i.v.
Trial: 7401741
Drug: Oxovinca; administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxovinca; administered over three consecutive courses within a two-month period.
Trial: 7401741
Drug: Placebo; administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; administered over three consecutive courses within a two-month period.
Trial: 27477804
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate (CS) 1,200 mg plus glucosamine sulfate (GS) 1,500 mg
Trial: 26055360
Drug: RG7667 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7667 (1, 3, 5, and 10 mg/kg each antibody; single ascending dose)
Trial: 26055360
Drug: RG7667 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7667 (5 and 10 mg/kg each antibody monthly for 3 doses; multiple ascending dose)
Trial: 26055360
Drug: RG7667 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7667 (10 mg/kg each antibody monthly for 3 doses; multiple dose expansion)
Trial: 23857311
Drug: Doxazosin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (8 mg/d)
Trial: 16728222
Drug: Rosuvastatin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (5 to 40 mg)
Trial: 9863080
Drug: Composite Divitriol
RxNorm normalized name: DRESSING,COMPOSITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite Divitriol Infusion (CDI)
Trial: 7945476
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) - transdermal estradiol (50 micrograms daily)
Trial: 7945476
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (400 mg daily)
Trial: 7945476
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) in patients taking steroids
Trial: 3555580
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg quinine bisulphate at night
Trial: 3555580
Drug: Increased nightly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased nightly dose of quinine
Trial: 24951828
Drug: Bivalent intramuscular
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent intramuscular norovirus virus-like particle vaccine (50 µg of each VLP)
Trial: 18192704
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol 0.75 mcg three times weekly for six weeks
Trial: 18192704
Drug: Oral alfacalcidol
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral alfacalcidol 0.75 mcg three times weekly for six weeks
Trial: 15983453
Drug: Liberal protocol
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal protocol group (LPG) - bolus of 10 ml/kg followed by 12 ml x kg(‐1) x h(‐1)
Trial: 15983453
Drug: Restrictive protocol
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive protocol group (RPG) - 4 ml x kg(‐1) x h(‐1)
Trial: 12028259
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg oral cyanocobalamin
Trial: 12028259
Drug: 10 microg
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg oral cyanocobalamin
Trial: 2028626
Drug: Actisomide 4.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actisomide 4.2 mg/kg
Trial: 2028626
Drug: Actisomide 8.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actisomide 8.4 mg/kg
Trial: 2028626
Drug: Actisomide 2.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actisomide 2.1 mg/kg
Trial: 27471050
Drug: Comprehensive care
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive care programme (IG) including education from a respiratory nurse, physiotherapist support for pulmonary rehabilitation, 3-monthly telephone calls by a respiratory nurse for 1 year, and follow-up at a respiratory clinic with a respiratory specialist once every 3 months for 1 year.
Trial: 9780750
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional fluid therapy)
Trial: 8166152
Drug: NPN (neomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPN (neomycin 250 mg QID, polymyxin‐B 100 mg QID, nalidixic acid 1,000 mg BID)
Trial: 26376650
Drug: Oral perhexiline
RxNorm normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral perhexiline for a median of 9 days
Trial: 23159133
Drug: Colloid solution
RxNorm normalized name: colloidal oatmeal Topical Solution
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colloid solution
Trial: 15170391
Drug: Crystalloid solution
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid solution
Trial: 18046927
Drug: Inhaled dry
RxNorm normalized name: Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dry powder insulin (IDPI)
Trial: 7914104
Drug: 2-chlorodeoxyadenosine (2-CdA)
RxNorm normalized name: 2-Chlorodeoxyadenosine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-chlorodeoxyadenosine (2-CdA) administered as a single 120-hour continuous infusion (8.9 mg/m2 of body surface area per day)
Trial: 3342158
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no thrombolytic treatment)
Trial: 30589098
Drug: Benidipine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine (8 mg)
Trial: 27240265
Drug: Befriending (supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befriending (supportive treatment)
Trial: 25365653
Drug: Topiramate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (300 mg)
Trial: 24182325
Drug: Cetrorelix (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix (5 mg/day on days 1 and 2; 3 mg/day on days 3-5)
Trial: 7993833
Drug: Preoperative combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative combined chemotherapy (TMF regimen: thiotepa 20 mg, methotrexate 40 mg/m2, 5-fluorouracil 500 mg/m2) plus radiotherapy (Group I)
Trial: 7993833
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation therapy only (Group II)
Trial: 7993833
Drug: Preoperative combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative combined chemotherapy plus radiotherapy (Group I)
Trial: 3140327
Drug: Metaproterenol solution
RxNorm normalized name: metaproterenol Inhalation Solution
DrugBank: Orciprenaline (DB00816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metaproterenol solution
Trial: 3140327
Drug: Cromolyn solution
RxNorm normalized name: cromolyn Oral Solution
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn solution
Trial: 26223254
Drug: Short implants
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short implants (6 mm) alone
Trial: 26223254
Drug: Short implants
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short implants (8 mm) combined with osteotome sinus floor elevation (OSFE)
Trial: 26223254
Drug: Standard implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard implants (10 mm) combined with osteotome sinus floor elevation (OSFE)
Trial: 20554506
Drug: Selective retina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective retina therapy (SRT) using Q-switched Nd:YLF laser, wavelength 527 nm, t=1.7 μs, energy 100-370 μJ, spot diameter 200 μm, pulse repetition rate 100 Hz
Trial: 18929279
Drug: Cisatracurium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.1 mg/kg (Group A)
Trial: 18929279
Drug: Cisatracurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.15 mg/kg (Group B)
Trial: 18929279
Drug: Cisatracurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.2 mg/kg (Group C)
Trial: 14652364
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg elemental iron with 1 mg riboflavin
Trial: 14652364
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg elemental zinc with 1 mg riboflavin
Trial: 14652364
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg iron and 20 mg zinc with 1 mg riboflavin
Trial: 14652364
Drug: Micronutrient mix
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient mix (MM) containing 20 mg iron, 20 mg zinc, 1 mg riboflavin along with other minerals and vitamins
Trial: 14652364
Drug: Control treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment, 1 mg riboflavin only
Trial: 1452950
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement containing protein (20.4 g), mineral salts (Ca: 0.525 g), and vitamins A = 750 IU; D3 = 25 IU, 250 ml/day for a mean of 38 days
Trial: 1452950
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received the same supplement dose but with no protein, 250 ml/day for a mean of 38 days
Trial: 6362490
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg of epinephrine
Trial: 6362490
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of phenylephrine
Trial: 6362490
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of phenylephrine
Trial: 6362490
Drug: Epinephrine and
RxNorm normalized name: Epinephrine and zinc only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine and phenylephrine (at equipotent doses)
Trial: 30275690
Drug: GLY 25
RxNorm normalized name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 25 g in 100 g TOPICAL STICK [Pit Boss Antiperspirant and Deodorant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLY 25 µg twice daily
Trial: 30275690
Drug: GLY 50
RxNorm normalized name: Gly
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GLY 50 µg twice daily
Trial: 30275690
Drug: TIO 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIO 18 µg once daily